Usefulness of technetium-99m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma

1993 ◽  
Vol 20 (12) ◽  
Author(s):  
F. Tenenbaum ◽  
M. Schlumberger ◽  
F. Bonnin ◽  
J. Lumbroso ◽  
B. Aubert ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Technetium 99M

131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

1987 ◽  
Vol 26 (03) ◽  
pp. 139-142 ◽  
Author(s):  
G. Arning ◽  
O. Schober ◽  
H. Hundeshagen ◽  
Ch. Ehrenheim
Keyword(s):  
Serum Level ◽  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Level ◽  
Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?

1992 ◽  
Vol 16 (4) ◽  
pp. 640-645 ◽  
Author(s):  
C. A. G. Proye ◽  
D. H. R. Dromer ◽  
B. M. Carnaille ◽  
A. J. P. Gontier ◽  
A. Goropoulos ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Radioactive Iodine ◽  
Differentiated Thyroid Carcinoma

scholarly journals Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma

2009 ◽  
Vol 161 (6) ◽  
pp. 923-931 ◽  
Author(s):  
Hendrieke Hoftijzer ◽  
Karen A Heemstra ◽  
Hans Morreau ◽  
Marcel P Stokkel ◽  
Eleonora P Corssmit ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Tumor Progression ◽  
Kinase Inhibitor ◽  
Treatment Options ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Mutational Status

ObjectiveTreatment options for patients with radioactive iodine (RaI) refractory metastases of differentiated thyroid carcinoma (DTC) are limited. We studied the effects of the multitarget tyrosine kinase inhibitor sorafenib on the reinduction of RaI uptake and tumor progression.DesignOpen, single center, single arm 26-week prospective phase II study with open-ended extension.MethodsWe treated 31 patients with progressive metastatic or locally advanced RaI refractory DTC with sorafenib 400 mg b.i.d. The primary endpoint was reinduction of RaI uptake at 26 weeks. Additional endpoints were the radiological response and the influence of bone metastases.ResultsAt 26 weeks of sorafenib therapy, no reinduction of RaI uptake at metastatic sites was observed, but 19 patients (59%) had a clinical beneficial response, eight of whom had a partial response (25%) and 11 had stable disease (34%). Seven patients had progressive disease (22%). Sorafenib was significantly less effective in patients with bone metastases. The estimated median progression free survival was 58 weeks (95% confidence interval, CI, 47–68). In general, thyroglobulin (Tg) response (both unstimulated and TSH stimulated) reflected radiological responses. The median time of the nadir of Tg levels was 3 months. Responses were not influenced by histological subtype, mutational status or other variables. No unusual side effects were observed.ConclusionsSorafenib has a beneficial effect on tumor progression in patients with metastatic DTC, but was less effective in patients with bone metastases. Diagnostic whole body scintigraphy did not reveal an effect of sorafenib on the reinduction of RaI uptake.

Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid Carcinoma

1986 ◽  
Vol 63 (4) ◽  
pp. 960-967 ◽  
Author(s):  
SCHLUMBERGER MARTIN ◽  
TUBIANA MAURICE ◽  
FLORENT DE VATHAIRE ◽  
HILL CATHERINE ◽  
PAULE GARDET ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Long Term Results ◽  
Results Of Treatment

Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma

1995 ◽  
Vol 22 (10) ◽  
pp. 1218-1220 ◽  
Author(s):  
Shigeru Kosuda ◽  
Hisaaki Yokoyama ◽  
Michiaki Katayama ◽  
Tokuzo Yokokawa ◽  
Shoichi Kusano ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Technetium 99M Sestamibi ◽  
Technetium 99M ◽  
Technetium 99M Tetrofosmin ◽  
Sestamibi Imaging ◽  
Multiple Metastases
Sign in / Sign up

Export Citation Format

Share Document